A Biopharma M&A Bonanza In 2022? Analysts Pick Top Targets And Likely Buyers

Big Pharma Will Have $530bn To Spend

 
• By Andrew McConaghie
Pfizer
Pfizer's COVID-19 vaccine windfall will help fuel its M&A strategy over the next 5 years. • Source: Alamy

More from Deals

More from Business